Traws Pharma, Inc. (NASDAQ:TRAW) Sees Significant Increase in Short Interest

Traws Pharma, Inc. (NASDAQ:TRAW) was the target of a large increase in short interest in January. As of January 15th, there was short interest totalling 141,900 shares, an increase of 1,956.5% from the December 31st total of 6,900 shares. Based on an average daily trading volume, of 503,100 shares, the short-interest ratio is currently 0.3 days. Approximately 5.2% of the company’s shares are sold short.

Traws Pharma Trading Up 2.4 %

NASDAQ:TRAW traded up $0.17 on Tuesday, reaching $7.22. The company’s stock had a trading volume of 46,434 shares, compared to its average volume of 155,822. Traws Pharma has a 1-year low of $4.06 and a 1-year high of $27.50. The stock’s 50-day moving average price is $6.68. The stock has a market cap of $26.35 million, a price-to-earnings ratio of -0.05 and a beta of 1.13.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.